AR and prostate carcinoma: In prostate cancer, for example, such genetic drivers include loss of NKX3.1 and PTEN, amplification of Myc and the androgen receptor (AR), Sox9 [5], and fusions of ETS family transcription factors to androgen-inducible promoters [6].